Cargando…

Efficacy and safety of saroglitazar in real‐world patients of non‐alcoholic fatty liver disease with or without diabetes including compensated cirrhosis: A tertiary care center experience

BACKGROUND AND AIM: Saroglitazar, a dual PPAR α/γ agonist, is useful in management of NAFLD and diabetic dyslipidemia. Here, we report the safety and efficacy of saroglitazar in NAFLD patients with or without diabetes including compensated cirrhosis. METHODS: Patients, started on saroglitazar 4 mg w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chaudhuri, Sujit, Dutta, Agnibha, Chakraborty, Sunil Baran Das
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wiley Publishing Asia Pty Ltd 2023
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10037031/ https://www.ncbi.nlm.nih.gov/pubmed/36968568 http://dx.doi.org/10.1002/jgh3.12878

Ejemplares similares

Saroglitazar in patients with non-alcoholic fatty liver disease and diabetic dyslipidemia: a prospective, observational, real world study
por: Goyal, Omesh, et al.
Publicado: (2020)

New dual peroxisome proliferator activated receptor agonist—Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence
por: Kaul, Upendra, et al.
Publicado: (2019)

Saroglitazar in Non-alcoholic Fatty Liver Disease From Bench to Bedside: A Comprehensive Review and Sub-group Meta-Analysis
por: Roy, Akash, et al.
Publicado: (2023)

Saroglitazar – A Potential Therapeutic Option in Treating NASH? [Letter]
por: Shuja, Syed Hasan, et al.
Publicado: (2021)

Saroglitazar improved hepatic steatosis and fibrosis by modulating inflammatory cytokines and adiponectin in an animal model of non-alcoholic steatohepatitis
por: Akbari, Rasoul, et al.
Publicado: (2021)

Saroglitazar for the treatment of hypertrig-lyceridemia in patients with type 2 diabetes: current evidence
por: Sosale, Aravind, et al.
Publicado: (2015)

Circulating granulocyte lifespan in compensated alcohol‐related cirrhosis: a pilot study
por: Potts, Jonathan R., et al.
Publicado: (2016)

Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models
por: Jain, Mukul R., et al.
Publicado: (2017)

Deciphering the Precise Target for Saroglitazar Associated Antiangiogenic Effect: A Computational Synergistic Approach
por: Dabral, Swarna, et al.
Publicado: (2023)

The PPAR α/γ Agonist Saroglitazar Improves Insulin Resistance and Steatohepatitis in a Diet Induced Animal Model of Nonalcoholic Fatty Liver Disease
por: Kumar, Divya P., et al.
Publicado: (2020)

Differences in Fecal Short-Chain Fatty Acids between Alcoholic Fatty Liver-Induced Cirrhosis and Non-alcoholic (Metabolic-Associated) Fatty Liver-Induced Cirrhosis
por: Cao, Xinlu, et al.
Publicado: (2023)

Observational Study of Effects of Saroglitazar on Glycaemic and Lipid Parameters on Indian Patients with Type 2 Diabetes
por: Chatterjee, Sanjay, et al.
Publicado: (2015)

Significant Reduction of Elevated Triglycerides and Liver Fibrosis in Diabetic Dyslipidemia with Saroglitazar: A Case Report
por: Roy, Sayak, et al.
Publicado: (2019)

Saroglitazar is noninferior to fenofibrate in reducing triglyceride levels in hypertriglyceridemic patients in a randomized clinical trial
por: Rodriguez-Gutierrez, Rene, et al.
Publicado: (2022)

Efficacy and safety of saroglitazar for the management of dyslipidemia: A systematic review and meta-analysis of interventional studies
por: Chhabra, Manik, et al.
Publicado: (2022)

An Observational Study of Reduction in Glycemic Parameters and Liver Stiffness by Saroglitazar 4 mg in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease
por: Mitra, Asis
Publicado: (2020)

Factors associated with hepatocellular carcinoma occurrence after HCV eradication in patients without cirrhosis or with compensated cirrhosis
por: Abe, Kazumichi, et al.
Publicado: (2020)

Who Treats Patients with Diabetes and Compensated Cirrhosis
por: Liu, Tsai-Ling, et al.
Publicado: (2016)

Liver stiffness and thrombin generation in compensated cirrhosis
por: Dillon, Audrey, et al.
Publicado: (2019)

Validation of modified fibrosis-4 index for predicting hepatocellular carcinoma in patients with compensated alcoholic liver cirrhosis
por: Kim, Ji Hyun, et al.
Publicado: (2018)

Frailty in Nonalcoholic Fatty Liver Cirrhosis: A Comparison with Alcoholic Cirrhosis, Risk Patterns, and Impact on Prognosis
por: Skladany, Lubomir, et al.
Publicado: (2021)

Alcohol and Cirrhosis
Publicado: (1898)

A Multicenter, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of Saroglitazar in Patients With Primary Biliary Cholangitis
por: Vuppalanchi, Raj, et al.
Publicado: (2021)

Small Bowel Abnormalities in Patients with Compensated Liver Cirrhosis
por: Aoyama, Taiki, et al.
Publicado: (2012)

Correction: Who Treats Patients with Diabetes and Compensated Cirrhosis
por: Liu, Tsai-Ling, et al.
Publicado: (2018)

Duodenal Permeability Is Associated With Mucosal Microbiota in Compensated Cirrhosis
por: Bloom, P.P., et al.
Publicado: (2022)

Ultrasound is highly specific in diagnosing compensated cirrhosis in chronic hepatitis C patients in real world clinical practice
por: Yen, Yi-Hao, et al.
Publicado: (2019)

Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis
por: Lampertico, Pietro, et al.
Publicado: (2020)

Rare leptin in non-alcoholic fatty liver cirrhosis: A case report
por: Nong, Yao-Bin, et al.
Publicado: (2022)

Oesophageal varices predict complications in compensated advanced non-alcoholic fatty liver disease
por: Pennisi, Grazia, et al.
Publicado: (2023)

Correction to: Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis
por: Lampertico, Pietro, et al.
Publicado: (2020)

The Survival of Septic Patients with Compensated Liver Cirrhosis Is Not Inferior to That of Septic Patients without Liver Cirrhosis: A Propensity Score Matching Analysis
por: Chang, Ya-Chun, et al.
Publicado: (2022)

Acquired Parkinson’s Disease in Alcoholic Cirrhosis: The Rarest Association
por: Dubey, Apurva, et al.
Publicado: (2023)

Frequency of minimal hepatic encepalopathy in illeterate patients with compensated cirrhosis
por: Zuberi, Bader Faiyaz, et al.
Publicado: (2016)

Lusutrombopag increases hematocytes in a compensated liver cirrhosis patient
por: Sakamaki, Akira, et al.
Publicado: (2017)

Compensated liver cirrhosis: Natural course and disease-modifying strategies
por: Kumar, Ramesh, et al.
Publicado: (2023)

Liver Cirrhosis in Alcoholics
por: Demeulenaere, L., et al.
Publicado: (1977)

Hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis
por: Tovo, Cristiane Valle, et al.
Publicado: (2023)

Alcohol related cognitive impairments in patients with and without cirrhosis
por: Angerville, B., et al.
Publicado: (2023)

British Society of Gastroenterology Best Practice Guidance: outpatient management of cirrhosis – part 1: compensated cirrhosis
por: Mansour, Dina, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_cr1ki5ig2316kcfkoauc2cocjk